progesterone receptor positive (PR )
Showing 1 - 25 of >10,000
Granulosa Cell Ovarian Cancer, Low Grade Serous Ovarian/ Primary Peritoneal Cancer, Endometrioid Endometrial Cancer Trial in
Recruiting
- Granulosa Cell Ovarian Cancer
- +2 more
- Onapristone ER
- Onapristone ER + Anastrozole
-
Basking Ridge, New Jersey
- +7 more
Aug 17, 2022
Breast Cancer Trial in United States (bicalutamide, diagnostic laboratory biomarker analysis, immunohistochemistry staining
Carcinoma, Ovarian Epithelial, Low Grade Serous Adenocarcinoma of Ovary Trial in Brescia, Genova (Letrozole tablets, carboplatin
Recruiting
- Carcinoma, Ovarian Epithelial
- Low Grade Serous Adenocarcinoma of Ovary
- Letrozole tablets
- carboplatin AUC 5 and paclitaxel 175 mg/m2
-
Brescia, BS, Italy
- +1 more
Oct 26, 2022
Breast Cancer Trial in São Paulo (radiation, procedure, other)
Recruiting
- Breast Cancer
- Radiotherapy
- +2 more
-
São Paulo, SP, BrazilICESP
Aug 5, 2022
Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Oral Complications Trial in Los Angeles (mucoadhesive
Completed
- Estrogen Receptor-positive Breast Cancer
- +7 more
- mucoadhesive oral wound rinse
- laboratory biomarker analysis
-
Los Angeles, CaliforniaJonsson Comprehensive Cancer Center
Sep 17, 2020
Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Invasive Ductal Breast Carcinoma Trial in Boston,
Active, not recruiting
- Estrogen Receptor-positive Breast Cancer
- +5 more
- PI3K inhibitor BYL719
- +3 more
-
Boston, Massachusetts
- +1 more
Oct 14, 2022
Estrogen Receptor Positive, HER2/Neu Negative, Invasive Breast Carcinoma Trial in Los Angeles (procedure, drug, other)
Terminated
- Estrogen Receptor Positive
- +16 more
- Biopsy of Breast
- +5 more
-
Los Angeles, CaliforniaUCLA / Jonsson Comprehensive Cancer Center
Sep 22, 2022
Estrogen Receptor Positive, HER2/Neu Negative, Invasive Breast Carcinoma Trial in Houston (Radiation Therapy, Therapeutic
Active, not recruiting
- Estrogen Receptor Positive
- +3 more
- Radiation Therapy
- Therapeutic Conventional Surgery
-
Houston, TexasM D Anderson Cancer Center
Jun 14, 2022
Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative Trial in United States (Biomarker Analysis,
Active, not recruiting
- Estrogen Receptor Negative
- +6 more
- Biomarker Analysis
- +3 more
-
Birmingham, Alabama
- +8 more
Feb 3, 2022
Androgen Receptor Positive, Estrogen Receptor Negative, HER2/Neu Negative Trial in United States (drug, other, biological)
Active, not recruiting
- Androgen Receptor Positive
- +5 more
- Enobosarm
- +2 more
-
Corona, California
- +6 more
Jun 8, 2022
HER2-positive Breast Cancer, Metastatic Cancer, Metastatic Breast Cancer Trial in Chicago, Minneapolis (ALX148, Fam-Trastuzumab
Recruiting
- HER2-positive Breast Cancer
- +17 more
- ALX148
- Fam-Trastuzumab Deruxtecan-Nxki
-
Chicago, Illinois
- +1 more
May 19, 2023
Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer Trial in
Terminated
- Estrogen Receptor-positive Breast Cancer
- +7 more
- everolimus
- +5 more
-
Atlanta, Georgia
- +2 more
Mar 10, 2022
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8 Trial
Withdrawn
- Anatomic Stage 0 Breast Cancer AJCC v8
- +28 more
- Carbon Dioxide Fractional Laser
- Questionnaire Administration
- (no location specified)
Jan 5, 2023
Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative Trial in Bellevue, Grand Island, Omaha (drug, other,
Active, not recruiting
- Estrogen Receptor Negative
- +15 more
- Cyclophosphamide
- +6 more
-
Bellevue, Nebraska
- +3 more
Nov 30, 2022
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8
Active, not recruiting
- Anatomic Stage II Breast Cancer AJCC v8
- +16 more
- Durvalumab
- Tremelimumab
-
Houston, TexasM D Anderson Cancer Center
Aug 18, 2022
Breast Cancer, HER2-negative Breast Cancer, ER Positive Breast Cancer Trial in Stanford (Infigratinib, Tamoxifen, Omnipaque 350)
Recruiting
- Breast Cancer
- +3 more
- Infigratinib
- +3 more
-
Stanford, CaliforniaStanford University
Feb 16, 2022
Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, KIT Positive Trial in Houston (Imatinib Mesylate,
Completed
- Anatomic Stage IV Breast Cancer AJCC v8
- +6 more
- Imatinib Mesylate
- Letrozole
-
Houston, TexasM D Anderson Cancer Center
Jan 14, 2020
Estrogen Receptor-positive Breast Cancer, Musculoskeletal Complications, Progesterone Receptor-positive Breast Cancer Trial in
Active, not recruiting
- Estrogen Receptor-positive Breast Cancer
- +9 more
- anastrozole
- +3 more
-
Boston, Massachusetts
- +1 more
Sep 9, 2022
Breast Cancer Trial in Washington, Baltimore (Outcomes4Me, Semi-structured interview)
Recruiting
- Breast Cancer
- Outcomes4Me
- Semi-structured interview
-
Washington, District of Columbia
- +1 more
Jan 13, 2023
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8 Trial in
Active, not recruiting
- Anatomic Stage 0 Breast Cancer AJCC v8
- +21 more
- Ipilimumab
- +2 more
-
Los Angeles, CaliforniaUCLA / Jonsson Comprehensive Cancer Center
Sep 22, 2022
Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer Trial in New
Suspended
- Estrogen Receptor-negative Breast Cancer
- +8 more
- pegylated liposomal doxorubicin hydrochloride
- +6 more
-
New Brunswick, New JerseyRutgers Cancer Institute of New Jersey
Sep 20, 2021
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8 Trial
Recruiting
- Anatomic Stage I Breast Cancer AJCC v8
- +20 more
- Focus Group
- +3 more
-
Sewell, New Jersey
- +6 more
Sep 14, 2022